Nymox Announces Completion of Enrollment for Phase 3 BPH Re-Injection Study
HASBROUCK HEIGHTS, N.J., July 11, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NYMX) is pleased to announce the completion of enrollment for Study NX02-0020, one of the Company's Phase 3 studies of NX-1207 for benign prostatic hyperplasia (BPH). The NX02-0020 study started in July 2011 and involved men who had previously participated in one of the earlier NX-1207 studies for BPH and in the current trial wished an open label injection of NX-1207. A recent Safety Committee meeting update on the trial indicated no significant safety concerns to date. Recruitment of new participants for this ongoing study is now completed. Efficacy results for Study NX02-0020 are expected near the end of this year.
Dr. Paul Averback, CEO of Nymox, said, "The rapid enrollment in this study has clearly demonstrated that patients are extremely comfortable with NX-1207 treatment and with its convenience. The feedback and comments we have received from urologists are very positive."
NX-1207 is in late stage Phase 3 development in the U.S. for BPH. Phase 3 trial activities of NX-1207 for BPH have recently begun in Europe sponsored by Recordati S.p.A., the company's European licensing partner. NX-1207 is administered directly into the prostate by a urologist in an office setting in an injection that does not require anaesthesia, sedation, or catheterization, takes only a few minutes and involves minimal discomfort to the patient. NX-1207 has thus far shown none of the adverse sexual side effects associated with approved medical and surgical treatments for BPH.
BPH is one of the most commonly diagnosed conditions in the male population. The condition can seriously impact the health and quality of life of middle aged and older men. It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and a high proportion of men as they age suffer from moderate to severe urinary problems and symptoms associated with BPH.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Roy Wolvin Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.comSource: Nymox Pharmaceutical Corporation 2012 GlobeNewswire, Inc.